Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: a post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

被引：0

作者：

Raab, Marc ^{[1
]}

Manier, Salomon ^{[2
]}

Prince, H. Miles ^{[3
]}

Nooka, Ajay ^{[4
]}

Kaedbey, Rayan ^{[5
]}

Hillengass, Jens ^{[6
]}

Ishida, Tadao ^{[7
]}

Sullivan, Sharon ^{[8
]}

Conte, Umberto ^{[8
]}

Leip, Eric ^{[8
]}

Viqueira, Andrea ^{[9
]}

Raje, Noopur ^{[10
]}

机构：

[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[2] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA USA

[5] McGill Univ, Montreal, PQ, Canada

[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[7] Japanese Red Cross Med Ctr, Tokyo, Japan

[8] Pfizer Inc, New York, NY USA

[9] Pfizer SLU, Madrid, Spain

[10] Massachusetts Gen Hosp, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-307

引用

页码：S207 / S208

页数：2